The Podcast by KevinMD cover image

Corporate greed and medical complicity fueled a $250,000 drug

The Podcast by KevinMD

00:00

How Acthar became expensive

Desai outlines how a company exploited FDA loopholes, reclassified Acthar as a biologic, and dramatically raised its price.

Play episode from 03:35
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app